Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ALK Abello increases investment in peanut allergy vaccine research

ALK Abello increases investment in peanut allergy vaccine research

17th December 2010

ALK Abello has announced that it will be allocating more funding towards research into the world's first vaccine for peanut allergies.

The company will pay two million euros (1.7 million pounds) to purchase additional shares in the French biotech company DBV Technologies, which is currently developing the promising vaccine.

DBV's treatment utilises an electro-charged patch to provide gradual uptake of the vaccine via the skin and is due to enter the late-stage clinical development phase thanks to the capital injection.

ALK has been investing in DBV since early 2009 and will now partner with the company to bring the treatment to market.

Jens Bager, president and chief executive officer of ALK Abello, said: "The investment in DBV is part of ALK's strategy to invest in the expansion of effective and patient-friendly vaccines against the most important allergies, including food allergies."

Last month, the firm published its financial report for the first nine months of the year, during which it experienced an 11 percent year-on-year growth in vaccine sales.ADNFCR-8000103-ID-800298004-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.